The Impact of the COVID-19 Outbreak on Patients’ Adherence to PCSK9 Inhibitors Therapy
暂无分享,去创建一个
P. Caso | P. Golino | A. D’Andrea | B. Liccardo | S. Sperlongano | V. Russo | G. Nigro | E. Romeo | V. Caso | S. Padula | F. Arenga
[1] D. Carretta,et al. The Impact of COVID-19 Outbreak on Syncope Units Activities in Italy: A Report from the Italian Multidisciplinary Working Group on Syncope (GIMSI) , 2021, International journal of environmental research and public health.
[2] A. Fiorelli,et al. Nursing Teleconsultation for the Outpatient Management of Patients with Cardiovascular Disease during COVID-19 Pandemic , 2021, International journal of environmental research and public health.
[3] A. Rapacciuolo,et al. Cardiac implantable electronic devices replacements in patients followed by remote monitoring during COVID-19 lockdown , 2021, European heart journal. Digital health.
[4] A. Rapacciuolo,et al. Cardiac pacing procedures during coronavirus disease 2019 lockdown in Southern Italy: insights from Campania Region , 2021, Journal of cardiovascular medicine.
[5] G. Cimmino,et al. Cardiovascular Comorbidities and Pharmacological Treatments of COVID-19 Patients Not Requiring Hospitalization , 2020, International journal of environmental research and public health.
[6] ESC / EAS Guidelines for the Treatment of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk , 2020, Digital Doctor.
[7] A. Rapacciuolo,et al. Arrhythmogenic syncope leading to cardiac rhythm management procedures during COVID-19 lockdown , 2020, Expert review of medical devices.
[8] P. Golino,et al. COVID-19 and Heart: From Clinical Features to Pharmacological Implications , 2020, Journal of clinical medicine.
[9] R. de Caterina,et al. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era , 2020, European heart journal.
[10] Elham Monaghesh,et al. The role of telehealth during COVID-19 outbreak: a systematic review based on current evidence , 2020, BMC Public Health.
[11] J. H. Gittell,et al. From Isolation to Coordination: How Can Telemedicine Help Combat the COVID-19 Outbreak? , 2020, medRxiv.
[12] Z. Memish,et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China , 2020, International Journal of Infectious Diseases.
[13] M. Sabatine,et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.
[14] Odyssey Outcomes Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018 .
[15] G. Limongelli,et al. Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience , 2017, Journal of cardiovascular medicine.
[16] R. Krauss,et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease , 2018 .
[17] Lawrence A Leiter,et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. , 2017, The lancet. Diabetes & endocrinology.
[18] Christian Sperber,et al. An upper and lower bound of the Medication Possession Ratio , 2017, Patient preference and adherence.
[19] Lale Tokgözoğlu,et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel , 2017, European heart journal.
[20] A. Keech,et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.
[21] R. Giugliano,et al. Cognitive Function in a Randomized Trial of Evolocumab. , 2017, The New England journal of medicine.
[22] T. McCormack,et al. Very low LDL‐C levels may safely provide additional clinical cardiovascular benefit: the evidence to date , 2016, International journal of clinical practice.
[23] Paul M Ridker,et al. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). , 2011, Journal of the American College of Cardiology.
[24] M. Gnant,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .
[25] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[26] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[27] W. Howard. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2007 .